Effect of methoxychlor and estradiol on cytochrome p450 enzymes in the mouse ovarian surface epithelium.
Although the ovarian surface epithelium (OSE) is responsive to hormones and endocrine-disrupting chemicals, little information is available on the metabolizing capabilities of the OSE. Thus, we tested the hypothesis that the OSE is capable of expressing genes regulating phase I metabolism of estrogen and the estrogenic endocrine disruptor methoxychlor (MXC). To test this hypothesis, we isolated mouse OSE cells and cultured them with vehicle (dimethylsulfoxide; DMSO), 3 microM MXC, or 0.1 microM 17beta-estradiol (E2) +/- the anti-estrogen ICI 182,780 (1 microM) for 14 days. After culture, the cells were subjected to quantitative real-time polymerase chain reaction for cytochrome P450s (CYPs) 1A1, 1B1, 2C29, and 1A2, and estrogen receptor alpha (ERalpha). Our results indicate that E2 and MXC did not alter the expression of CYP1A1 or CYP1A2. In contrast, E2 significantly increased expression of CYP1B1 compared to controls (DMSO = 0.93 +/- 0.1, E2 = 3.12 +/- 0.64 genomic equivalents (GE), n = 4, p < or = 0.01). The E2-induced increase in CYP1B1 was abolished by co-treatment with ICI 182,780 (0.41 +/- 0.17 GE). MXC treatment did not affect CYP1B1 expression. Both MXC and E2 increased expression of CYP2C29 (DMSO = 0.02 +/- 0.003; MXC = 0.04 +/- 0.008; E2 = 0.46 +/- 0.03 GE, n = 4, p < or = 0.05). MXC- and E2-induced elevations in CYP2C29 were abolished by co-treatment with ICI 182,780 (0.02 +/- 0.005; 0.02 +/- 0.07 GE). In addition, E2 increased ERalpha expression 15-fold compared to controls (DMSO = 1.10 +/- 0.09, E2 = 15.0 +/- 3.60 GE, n = 3, p < or = 0.05), and ICI 182,780 abolished the E2-induced increase in ERalpha expression (1.85 +/- 1.09 GE). MXC treatment did not affect ERalpha expression. These data indicate that the OSE expresses enzymes known to metabolize native and xenoestrogens and that MXC and E2 modulate expression of some of them through ER-linked mechanisms.
Symonds
Daniel A
DA
Program in Toxicology, Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
Miller
Kimberly P
KP
Tomic
Dragana
D
Flaws
Jodi A
JA
D000818:Animals; D002478:Cells, Cultured; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis*; D052244:Endocrine Disruptors / Q000493:pharmacokinetics / Q000633:toxicity*; D004790:Enzyme Induction; D004847:Epithelial Cells / Q000187:drug effects* / Q000201:enzymology; D004958:Estradiol / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology*; D020847:Estrogen Receptor Modulators / Q000494:pharmacology; D047628:Estrogen Receptor alpha / Q000096:biosynthesis; D005260:Female; D000077267:Fulvestrant; D050216:Metabolic Detoxication, Phase I; D008731:Methoxychlor / Q000493:pharmacokinetics / Q000633:toxicity*; D051379:Mice; D008815:Mice, Inbred Strains; D010053:Ovary / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D016133:Polymerase Chain Reaction
D052244:Endocrine Disruptors; D020847:Estrogen Receptor Modulators; D047628:Estrogen Receptor alpha; D000077267:Fulvestrant; D004958:Estradiol; D003577:Cytochrome P-450 Enzyme System; D008731:Methoxychlor